Logo

Myriad Genetics Precise Oncology Solutions

Mar 14, 2022

Myriad Genetics announced the launch of Precise Oncology Solutions, a new service through which oncologists can order its BRACAnalysis CDx and MyChoice CDx; its MyRisk Hereditary Cancer Test; and the Precise Tumor Molecular Profile Test, which is performed at a CLIA-certified lab operated by Intermountain Healthcare. Myriad and Intermountain, both headquartered in Salt Lake City, Utah, have been working on this combined offering for the past year to streamline oncologists' access to next-generation sequencing-based germline and somatic analysis, which can inform patients' inherited cancer risks and expand their personalized treatment opportunities. Doctors can order all the tests offered through this service and receive results via a new online portal. Myriad also said it will share with researchers deidentified genomic and clinical data from patients tested through this service within a new Precise Treatment Registry, powered by DNANexus' bioinformatics platform.

Breaking News
The Scan

Cancer Survival Linked to Mutational Burden in Pan-Cancer Analysis

A pan-cancer paper appearing in JCO Precision Oncology suggests tumor mutation patterns provide clues for predicting cancer survival that are independent of other prognostic factors.

Australian Survey Points to Public Support for Genetic Risk Disclosure in Relatives of At-Risk Individuals

A survey in the European Journal of Human Genetics suggests most adult Australians are in favor of finding out if a relative tests positive for a medically actionable genetic variant.

Study Links Evolution of Stony Coral Skeleton to Bicarbonate Transporter Gene

A PNAS paper focuses on a skeleton-related bicarbonate transporter gene introduced to stony coral ancestors by tandem duplication.

Hormone-Based Gene Therapy to Sterilize Domestic Cat

A new paper in Nature Communication suggests that gene therapy could be a safer alternative to spaying domestic cats.